Page last updated: 2024-08-21

alpha-aminopyridine and Colitis Gravis

alpha-aminopyridine has been researched along with Colitis Gravis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
El-Adawy, SA; El-Ashmawy, NE; El-Bahrawy, HA; Khedr, NF	1

Other Studies

1 other study(ies) available for alpha-aminopyridine and Colitis Gravis

Article	Year
Roflumilast, type 4 phosphodiesterase inhibitor, attenuates inflammation in rats with ulcerative colitis via down-regulation of iNOS and elevation of cAMP. International immunopharmacology, 2018, Volume: 56 Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Colitis, Ulcerative; Colon; Cyclic AMP; Cyclopropanes; Dextran Sulfate; Disease Models, Animal; Down-Regulation; Humans; Male; Nitric Oxide; Nitric Oxide Synthase Type II; Phosphodiesterase 4 Inhibitors; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha; Up-Regulation	2018

Article

Year

Roflumilast, type 4 phosphodiesterase inhibitor, attenuates inflammation in rats with ulcerative colitis via down-regulation of iNOS and elevation of cAMP.

International immunopharmacology, 2018, Volume: 56

Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Colitis, Ulcerative; Colon; Cyclic AMP; Cyclopropanes; Dextran Sulfate; Disease Models, Animal; Down-Regulation; Humans; Male; Nitric Oxide; Nitric Oxide Synthase Type II; Phosphodiesterase 4 Inhibitors; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha; Up-Regulation

2018